FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Express News | Shenzhen Kangtai Biological Products: The 20-valent pneumococcal polysaccharide conjugate vaccine has initiated phase I clinical trials.
Hong Kong stocks fluctuate | zai lab (09688) rises over 5% as it reaches a collaboration in mainland china with pfizer on a new antibacterial drug.
zai lab (09688) rose more than 5%, as of the deadline, up 5.26%, trading at 20.8 Hong Kong dollars, with a turnover of 7.8692 million Hong Kong dollars.
Laurel Lee From Florida's 15th District Makes Notable Trades in Apple, GE Vernova, and Pfizer
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively